Previous Close | 64.50 |
Open | 63.70 |
Bid | 61.70 |
Ask | 65.10 |
Strike | 105.00 |
Expire Date | 2025-01-17 |
Day's Range | 63.70 - 65.02 |
Contract Range | N/A |
Volume | |
Open Interest | 90 |
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.